Inovio Pharmaceuticals (INO) has emerged as a primary target for short-squeeze volatility. According to data from Tapeboard, the stock currently holds a squeeze score of 92.8, the highest among tracked US equities. With 22.2% of its float currently sold short and a borrow fee of 22.1%, the cost of maintaining these bearish positions is significant. The days-to-cover ratio sits at 0.8, suggesting that any sudden upward price movement could force a rapid scramble for shares. Investors should note that while short interest is based on the latest FINRA settlement data, the high borrow fee and elevated squeeze score indicate that the lending market is under considerable stress.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.